Method and probes for the detection of a tumor-specific...

Chemistry: molecular biology and microbiology – Measuring or testing process involving enzymes or... – Involving antigen-antibody binding – specific binding protein...

Reexamination Certificate

Rate now

  [ 0.00 ] – not rated yet Voters 0   Comments 0

Details

C435S007500, C435S007910, C435S007920, C435S069700, C436S018000, C436S501000, C422S050000, C422S067000

Reexamination Certificate

active

07993850

ABSTRACT:
The invention relates to the detection of fusion proteins. Described are a set of at least a first and a second molecular probe, each probe provided with a dye wherein the dyes together allow energy transfer, at least one probe provided with a reactive group allowing juxtaposing at least the first and second probes wherein the reactive group allows modulation of juxtaposing the probes such that there is an increased likelihood of energy transfer between the dyes. A method is provided which permits detecting the presence of a fusion protein in a cell at the single cell level.

REFERENCES:
patent: 5091206 (1992-02-01), Wang et al.
patent: 5369008 (1994-11-01), Arlinghaus et al.
patent: 5514340 (1996-05-01), Lansdorp et al.
patent: 6107457 (2000-08-01), Arlinghaus et al.
patent: 6159748 (2000-12-01), Hechinger
patent: 6610498 (2003-08-01), Berendes et al.
patent: 6686165 (2004-02-01), Van Dongen et al.
patent: 7387897 (2008-06-01), Wognum et al.
patent: 7575874 (2009-08-01), van Dongen
patent: 2002/0042056 (2002-04-01), van Dongen et al.
patent: 2004/0110245 (2004-06-01), Nagamune et al.
patent: 1 382 965 (2004-01-01), None
patent: WO 92/21032 (1992-11-01), None
patent: WO 98/53317 (1998-11-01), None
patent: WO 01/75453 (2001-10-01), None
patent: WO 02/054074 (2002-07-01), None
patent: WO 02/088733 (2002-11-01), None
patent: WO 2004/042398 (2004-05-01), None
patent: WO 2005/015235 (2005-02-01), None
#Emig et al., Accurate and rapid analysis of residual disease in patients with CML using specific fluorescent hybridization probes for real time quantitative RT-PCR, Leukemia. 1999, pp. 1825-1832. vol. 13. No. 11.
#Ueda et al., Homogeneous Noncompetitive Immunoassay Based on the Energy Transfer Between Fluorolabeled Antibody Variable Domains (Open Sandwich Fluoroimmunoassay), BioTechniques, Oct. 1999. pp. 738-742. vol. 27.
#PCT International Preliminary Examination Report, PCT/NL03/00776, dated Feb. 10, 2005.
#PCT International Search Report, PCT/NL03/00776, dated Mar. 12, 2004.
PCT International Search Report, PCT/NL2004/000562, dated Dec. 6, 2004.
Cordell et al., “Detection of Normal and Chimeric Nuleophosim in Human Cells,” Blood, Jan. 15, 1999, pp. 632-642, vol. 93, No. 2.
Nagasaki et al., An enzyme immunoassay for carcinoembryonic antigen with homogeneous reactivity to different CEA preparations and low cross-reactivity with CEA-related normal antigens, Journal of Immunological Methods. 1993. pp. 235-245, vol. 162.
Van Denderen et al., Antibody recognition of the tumor-specific bcr-abl joining region in Chronic Myeloid Leukemia. J. Exp. Med. Jan. 1989, pp. 87-98, vol. 169.
Co-pending U.S. Appl. No. 11/122,775, filed May 5, 2005, Van Dongen, Method and Probes for the Detection of a Tumor Specific Fusion Protein.
Co-pending U.S. Appl. No. 11/351,879, filed Feb. 10, 2006, Staal et al., Method for Detecting Low Levels of a Fusion Protein.

LandOfFree

Say what you really think

Search LandOfFree.com for the USA inventors and patents. Rate them and share your experience with other people.

Rating

Method and probes for the detection of a tumor-specific... does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Method and probes for the detection of a tumor-specific..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Method and probes for the detection of a tumor-specific... will most certainly appreciate the feedback.

Rate now

     

Profile ID: LFUS-PAI-O-2795259

  Search
All data on this website is collected from public sources. Our data reflects the most accurate information available at the time of publication.